Related Experiment Video

Updated: Apr 11, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.9K

Choline-positron emission tomography/CT in patients with relapsing prostate cancer: to be performed with therapeutic

Axel Heidenreich1

  • 1Department of Urology, Uniklinik RWTH University Aachen, Aachen, Germany.

BJU International
|May 29, 2015
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

10.6K
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

1.1K

Related Experiment Videos

Last Updated: Apr 11, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.9K
A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

10.6K
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

1.1K

Related Concept Videos

Positron Emission Tomography01:29

Positron Emission Tomography

8.1K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
8.1K
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

775
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
775

Articles linked to this work by shared authors, journal, and citation graph.

Diagnostic performance of the microRNA-371a assay in small testicular masses: a real-world cohort study.

BJU international·2026

NECTIN4 Amplification Is a Frequent Event in Central Nervous System Metastases of Urothelial Carcinoma.

European urology open science·2026

[Diagnosis and treatment of urothelial carcinoma of the bladder with divergent histology].

Urologie (Heidelberg, Germany)·2026

Diagnostic Performance and Clinical Utility of the Uromonitor® Molecular Urine Assay for Urothelial Carcinoma of the Bladder: A Systematic Review and Diagnostic Accuracy Meta-Analysis.

Diagnostics (Basel, Switzerland)·2026

[Indication and outcome of salvage surgery for urogenital malignancies].

Urologie (Heidelberg, Germany)·2026

Expert Genitourinary Pathology Review of Orchiectomy Specimens Should Be Mandatory for Optimal Management. Recommendations from the European Association of Urology Guidelines Panel on Testicular Cancer.

European urology·2025

[18F]fluorodeoxyglucose PET/CT refines staging and treatment selection in high-risk upper tract urothelial carcinoma.

BJU international·2026

Transurethral ultrasound ablation (TULSA) for prostate cancer: a systematic review and meta-analysis.

BJU international·2026

Prognostic biomarkers in non-muscle-invasive bladder cancer: biological basis and evidence.

BJU international·2026

Surgical waiting times in patients with high- and low-risk renal cell carcinoma in England.

BJU international·2026

Comparative accuracy of imaging modalities for differentiating malignant small testicular masses.

BJU international·2026

A novel ureteric stent coating reduces encrustation and improves tolerability in a randomised trial.

BJU international·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us